Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasms, Second Primary × Trastuzumab × 1 year × Clear all

Status

Active not recruiting 1

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Breast Neoplasms 101 Stomach Neoplasms 17 HER2-positive Breast Cancer 13 Neoplasms 11 Neoplasm Metastasis 9 Colorectal Neoplasms 9 Esophageal Neoplasms 7 Triple Negative Breast Neoplasms 4 Meningeal Neoplasms 4 Colonic Neoplasms 4 Brain Neoplasms 4 Adenocarcinoma Of Esophagus 4 Salivary Gland Neoplasms 3 Rectal Neoplasms 3 Meningeal Carcinomatosis 3 Lymphoma, Non-Hodgkin 3 Lung Neoplasms 3 Gallbladder Neoplasms 3 Endometrial Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Biliary Tract Neoplasms 3 Anatomic Stage I Breast Cancer AJCC v8 3 Solid Tumors 2 Prostatic Neoplasms 2 Pathologic Complete Response 2 Ovarian Neoplasms 2 Multiple Myeloma 2 Inflammatory Breast Neoplasms 2 Hematologic Neoplasms 2 HER2-positive Gastric Cancer 2

Interventions

avelumab 1 Varenicline 1 Tyrosine Kinase Inhibitors 1 Trastuzumab 1 Tobacco Use Cessation Devices 1 Registries 1 Probiotics 1 Patient Reported Outcome Measures 1 Nicotine Chewing Gum 1 Leucovorin 1 Lenalidomide 1 Irinotecan 1 Interviews as Topic 1 Fluorouracil 1 Cisplatin 1 Cetuximab 1 Bupropion 1 Bleomycin 1 Anthracyclines 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03199300 2025-12-11

InvestiCAT

University Medical Center Groningen

Active not recruiting

Neoplasms, Second Primary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡